Gwenn Hansen sold $39k of NRIX
Chief Scientific Officer at Nurix Therapeutics, Inc.. 3,377 shares at an average of $11.50, traded Apr 30, 2025, filed Apr 30, 2025.
Score components
- +15RoleOfficer
- +6Trade size$39k at market
- 0Share of holdings soldSold 5.2% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001549595-25-000061, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 30, 2025 | MOption exercise Common Stock | +3,206 | $0.00 | $0 | 59,143 | Apr 30, 2025 |
| Apr 30, 2025 | MOption exercise Common Stock | +2,000 | $0.00 | $0 | 61,143 | Apr 30, 2025 |
| Apr 30, 2025 | MOption exercise Common Stock | +3,750 | $0.00 | $0 | 64,893 | Apr 30, 2025 |
| Apr 30, 2025 | SOpen-market sale Common Stock | -3,377 | $11.50 | $39k | 61,516 | Apr 30, 2025 |
| Apr 30, 2025 | MOption exercise Restricted Stock Unitsderivative | -3,206 | $0.00 | $0 | 9,621 | Apr 30, 2025 |
| Apr 30, 2025 | MOption exercise Restricted Stock Unitsderivative | -2,000 | $0.00 | $0 | 8,000 | Apr 30, 2025 |
| Apr 30, 2025 | MOption exercise Restricted Stock Unitsderivative | -3,750 | $0.00 | $0 | 30,000 | Apr 30, 2025 |
Related signals
Other insiders at Nurix Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 1Weak | Nurix Therapeutics, Inc. | Christine Ring Chief Legal Officer | $134k 5,786 shares | -39% | |
| 9Weak | Nurix Therapeutics, Inc. | Christine Ring Chief Legal Officer | $149k 5,787 shares | -39% | |
| 0Weak | Nurix Therapeutics, Inc. | Gwenn Hansen Chief Scientific Officer | $37k 1,452 shares | -1% | |
| 0Weak | Nurix Therapeutics, Inc. | Christine Ring Chief Legal Officer | $67k 3,760 shares | -7% | |
| 10Weak | Nurix Therapeutics, Inc. | Christine Ring Chief Legal Officer | $642k 37,600 shares | -42% | |
| 31Weak | Nurix Therapeutics, Inc. | Hans van Houte Chief Financial Officer | $79k 6,284 shares | -14% | |
| 22Weak | Nurix Therapeutics, Inc. | Gwenn Hansen Chief Scientific Officer | $52k 4,087 shares | -5% | |
| 21Weak | Nurix Therapeutics, Inc. | Christine Ring Chief Legal Officer | $47k 3,644 shares | -7% | |
| 28Weak | Nurix Therapeutics, Inc. | Hans van Houte Chief Financial Officer | $40k 3,130 shares | -7% | |
| 29Weak | Nurix Therapeutics, Inc. | Hans van Houte Chief Financial Officer | $60k 5,402 shares | -13% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.